NVCN Neovasc Inc

 

Securities and Exchange Commission

w ashington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

 

For the month of	November		2018
Commission File Number	001-36458
Neovasc Inc.
(Translation of registrant’s name into English)
Suite 5138 - 13562 Maycrest Way Richmond, British Columbia, Canada, V6V 2J7
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F

☒

Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):           

 

            Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):           

 

 

 

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

 

Document
Document 1		News Release dated November 7, 2018 - Neovasc Announces Third Quarter 2018 Financial Results Conference Call and Webcast

 

DOCUMENT 1

 

 

 

 

Neovasc Announces Third Quarter 2018 Financial Results Conference Call and Webcast

NASDAQ, TSX: NVCN

VANCOUVER, Nov. 7, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter and nine months ended September 30, 2018 and host a conference call and webcast at 4:30pm Eastern Time on Wednesday, November 14, 2018.

Conference Call & Webcast

Wednesday, November 14th @ 4:30pm Eastern Time
Domestic:	855-283-1097
International:	323-794-2575
Passcode:	7885315
Webcast:	http://public.viavid.com/index.php?id=131832
Replays available through November 28 th :
Domestic:	844-512-2921
International:	412-317-6671
Conference ID:	7885315

 

About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™ (the "Tiara"), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States , Canada and Europe . For more information, visit: www.neovasc.com.

View original content:http://www.prnewswire.com/news-releases/neovasc-announces-third-quarter-2018-financial-results-conference-call-and-webcast-300745342.html

SOURCE Neovasc Inc.

 

View original content: http://www.newswire.ca/en/releases/archive/November2018/07/c1611.html

%CIK: 0001399708

For further information: Chris Clark, Chief Financial Officer, Neovasc Inc., 604 248-4138, cclark@neovasc.com; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568

CO: Neovasc Inc.

CNW 07:30e 07-NOV-18

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

				Neovasc Inc.
				(Registrant)
Date:		November 7, 2018		By:	/s/ Chris Clark
					Name: Chris Clark Title: Chief Financial Officer